Albuterol and Ipratropium Dosing for COPD and Asthma
For acute exacerbations of COPD or asthma, the recommended dosing regimen is albuterol 2.5-5 mg nebulized solution every 20 minutes for 3 doses, then every 1-4 hours as needed, with ipratropium 0.5 mg added to the nebulizer solution for the first 3 doses. 1
Nebulizer Solution Dosing
Adults:
Albuterol nebulizer solution (0.083%):
- 2.5-5 mg every 20 minutes for 3 doses
- Then 2.5-10 mg every 1-4 hours as needed
- Alternative: 10-15 mg/hour by continuous nebulization 1
Ipratropium nebulizer solution (0.02%):
Combination (ipratropium with albuterol):
Children:
Albuterol nebulizer solution:
- 0.15 mg/kg (minimum dose 2.5 mg) every 20 minutes for 3 doses
- Then 0.15-0.3 mg/kg up to 10 mg every 1-4 hours as needed
- Alternative: 0.5 mg/kg/hour by continuous nebulization 1
Ipratropium nebulizer solution:
- 0.25-0.5 mg every 20 minutes for 3 doses
- Then as needed 1
Combination (ipratropium with albuterol):
- 1.5 mL every 20 minutes for 3 doses
- Then as needed 1
Metered-Dose Inhaler (MDI) Dosing
Adults:
Albuterol MDI (90 mcg/puff):
- 4-8 puffs every 20 minutes up to 4 hours
- Then every 1-4 hours as needed 1
Ipratropium MDI (18 mcg/puff):
- 8 puffs every 20 minutes as needed up to 3 hours 1
Combination MDI (18 mcg ipratropium/90 mcg albuterol per puff):
- 8 puffs every 20 minutes as needed up to 3 hours 1
Children:
Albuterol MDI (90 mcg/puff):
- 4-8 puffs every 20 minutes for 3 doses
- Then every 1-4 hours as needed 1
Ipratropium MDI (18 mcg/puff):
- 4-8 puffs every 20 minutes as needed up to 3 hours 1
Combination MDI (18 mcg ipratropium/90 mcg albuterol per puff):
- 4-8 puffs every 20 minutes as needed up to 3 hours 1
Clinical Considerations
Efficacy and Benefits
- The combination of ipratropium and albuterol provides greater bronchodilation than either agent alone 3, 4
- Combined therapy results in:
Administration Techniques
For nebulizer solutions:
For MDIs:
Important Caveats
- The addition of ipratropium to albuterol has not been shown to provide further benefit once the patient is hospitalized 1
- Ipratropium should not be used as first-line therapy; it should be added to short-acting beta-agonist (SABA) therapy for severe exacerbations 1
- For maintenance therapy in stable COPD, longer-acting agents (e.g., tiotropium) may be more appropriate than the ipratropium/albuterol combination 6, 7
By following these dosing guidelines and administration techniques, you can optimize bronchodilation and improve outcomes in patients with COPD or asthma exacerbations.